Security
Caribou Biosciences, Inc. Common Stock · CRBU
CRBUNASDAQCommon stockCurrentCIK 1619856Updated Oct 7, 2026
CRBU price & chart
Loading TradingView…
NASDAQ:CRBU on TradingView ↗About the company
Caribou is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. Caribou’s chRDNA genome-editing technology enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. For more information, please visit www.cariboubio.com.
In the news
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference ↗
CRBU Deadline: CRBU Investors Have Opportunity to Lead Caribou Biosciences, Inc. Securities Fraud Lawsuit News provided by THE ROSEN LAW FIRM, P. A. Feb 24, 2025, 17:05 ET Share this article Share to X Share this article Share to X NEW YORK , Feb. 24, 2025 /PRNewswire/ -- Rosen Law Firm, a global in ↗
Shareholders of Caribou Biosciences, Inc. Should Contact The Gross Law Firm Before February 24, 2025 to Discuss Your Rights - CRBU News provided by The Gross Law Firm Feb 24, 2025, 05:45 ET Share this article Share to X Share this article Share to X NEW YORK , Feb. 24, 2025 /PRNewswire/ -- The Gross ↗
Recent filings
Costs Associated with Exit or Disposal Activities · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure · Other Events
Items 2.05, 5.02, 7.01, 8.01, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Submission of Matters to a Vote of Security Holders
Items 5.07, 9.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 175,367,000Source | 313,313,000Source | 432,209,000Source | 373,765,000Source |
| Property, Plant and Equipment, NetUSD | 6,760,000Source | 19,281,000Source | 18,270,000Source | 10,678,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 12,360,000Source | 16,293,000Source | 51,162,000Source | 58,338,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 69,000Source | 265,000Source | 148,000Source | 202,000Source |
| Assets, CurrentUSD | 145,232,000Source | 219,377,000Source | 338,841,000Source | 260,248,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,913,000Source | 6,589,000Source | 6,155,000Source | 7,921,000Source |
| Operating Lease, Right-of-Use AssetUSD | 17,670,000Source | 20,009,000Source | 22,182,000Source | 24,230,000Source |
| Other Assets, NoncurrentUSD | 2,200,000Source | 5,521,000Source | 1,586,000Source | 1,538,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 53,192,000Source | 60,362,000Source | 63,808,000Source | 72,894,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | — | — | — | 0Source |
| Common Stock, Value, IssuedUSD | 9,000Source | 9,000Source | 8,000Source | 6,000Source |
| Additional Paid in CapitalUSD | 718,578,000Source | 701,077,000Source | 667,648,000Source | 499,598,000Source |
| Retained Earnings (Accumulated Deficit)USD | -596,515,000Source | -448,390,000Source | -299,285,000Source | -197,215,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 103,000Source | 255,000Source | 30,000Source | -1,518,000Source |
| Stockholders' Equity Attributable to ParentUSD | 122,175,000Source | 252,951,000Source | 368,401,000Source | 300,871,000Source |
| Liabilities and EquityUSD | 175,367,000Source | 313,313,000Source | 432,209,000Source | 373,765,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 25,414,000Source | 30,651,000Source | 28,302,000Source | 28,128,000Source |
| Operating Lease, Liability, CurrentUSD | 1,201,000Source | 1,426,000Source | 1,200,000Source | 966,000Source |
| Accounts Payable, CurrentUSD | 5,783,000Source | 2,476,000Source | 3,120,000Source | 1,146,000Source |
| Operating Lease, Liability, NoncurrentUSD | 26,026,000Source | 25,061,000Source | 25,908,000Source | 26,780,000Source |
| Deferred Income Tax Liabilities, NetUSD | 0Source | 548,000Source | 557,000Source | 381,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 16,535,000Source | 23,620,000Source | 21,135,000Source | 16,079,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 142,800,000Source | 249,400,000Source | 372,400,000Source | 317,000,000Source |
| Deferred Tax Liabilities, NetUSD | — | 548,000Source | 557,000Source | 381,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -148,125,000Source | -149,105,000Source | -102,070,000Source | -99,421,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 3,645,000Source | 3,927,000Source | 3,525,000Source | 1,622,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 12,680,000Source | 16,706,000Source | 13,750,000Source | 11,716,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -196,000Source | 117,000Source | -54,000Source | -951,000Source |
| Increase (Decrease) in Accounts PayableUSD | 3,254,000Source | -354,000Source | 1,819,000Source | -2,721,000Source |
| Deferred Income Tax Expense (Benefit)USD | -551,000Source | -10,000Source | 178,000Source | -95,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -110,992,000Source | -138,200,000Source | -93,291,000Source | -90,966,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 102,238,000Source | 86,607,000Source | -68,183,000Source | -93,249,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 1,359,000Source | 4,880,000Source | 11,613,000Source | 6,454,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 4,821,000Source | 16,724,000Source | 154,298,000Source | 2,133,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -3,933,000Source | -34,869,000Source | -7,176,000Source | -182,082,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 12,406,000Source | 16,339,000Source | 51,208,000Source | 58,384,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | — | 0Source | 170,000Source | 0Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 12,680,000Source | 16,706,000Source | 13,750,000Source | 11,716,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 142,800,000Source | 249,400,000Source | 372,400,000Source | 317,000,000Source |
| Equity Securities, FV-NI, Gain (Loss)USD | -99,000Source | -111,000Source | -6,000Source | -133,000Source |
| Gain (Loss) on Disposition of AssetsUSD | 25,000Source | 9,000Source | 34,000Source | 0Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | 0Source |
| General and Administrative ExpenseUSD | 37,914,000Source | 46,457,000Source | 38,461,000Source | 38,020,000Source |
| Income Tax Expense (Benefit)USD | -550,000Source | -9,000Source | 193,000Source | 70,000Source |
| Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment LossUSD | — | — | — | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -148,125,000Source | -149,105,000Source | -102,070,000Source | -99,421,000Source |
| Nonoperating Income (Expense)USD | -331,000Source | 17,502,000Source | 14,182,000Source | 7,048,000Source |
| Operating ExpensesUSD | 159,503,000Source | 176,610,000Source | 150,536,000Source | 120,250,000Source |
| Operating Lease, ExpenseUSD | — | — | 1,800,000Source | 1,800,000Source |
| Proceeds from Issuance of Common StockUSD | 4,070,000Source | 15,192,000Source | 1,007,000Source | — |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | 252,868,000Source |
| Restructuring Costs and Asset Impairment ChargesUSD | 14,426,000Source | — | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 11,159,000Source | 9,994,000Source | 34,477,000Source | 13,851,000Source |
| Operating Income (Loss)USD | -148,344,000Source | -166,616,000Source | -116,059,000Source | -106,399,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -148,675,000Source | -149,114,000Source | -101,877,000Source | -99,351,000Source |
| Income Tax Expense (Benefit)USD | -550,000Source | -9,000Source | 193,000Source | 70,000Source |
| Net Income (Loss) Attributable to ParentUSD | -148,125,000Source | -149,105,000Source | -102,070,000Source | -99,421,000Source |
| Earnings Per Share, BasicUSD per share | -1.59Source | -1.65Source | -1.38Source | -1.64Source |
| Earnings Per Share, DilutedUSD per share | -1.59Source | -1.65Source | -1.38Source | -1.64Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 93,389,283Source | 90,317,925Source | 73,807,597Source | 60,801,133Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 93,389,283Source | 90,317,925Source | 73,807,597Source | 60,801,133Source |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | 1,000Source | 1,000Source | 15,000Source | 165,000Source |
| General and Administrative ExpenseUSD | 37,914,000Source | 46,457,000Source | 38,461,000Source | 38,020,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -148,700,000Source | -149,100,000Source | -101,900,000Source | -99,400,000Source |
| Nonoperating Income (Expense)USD | -331,000Source | 17,502,000Source | 14,182,000Source | 7,048,000Source |
| Operating ExpensesUSD | 159,503,000Source | 176,610,000Source | 150,536,000Source | 120,250,000Source |
| Operating Lease, ExpenseUSD | — | — | 1,800,000Source | 1,800,000Source |
| Other IncomeUSD | 8,000,000Source | 15,300,000Source | 15,300,000Source | 4,600,000Source |
| Research and Development ExpenseUSD | 109,439,000Source | 130,153,000Source | 112,075,000Source | 82,230,000Source |
Filing attachments
d235175dex991.htm · 8-K · 2026-10-06
Exhibit 99.1 Caribou Biosciences to Evaluate Strategic Alternatives - Company to evaluate strategic alternatives to maximize stockholder value - - Caribou plans to discontinue vispa-cel and CB-011 allogeneic CAR-T cell therapy programs - - Cash, cash equivalents, and marketable securities of $113.8 million as of June 30, 2026 - BERKELEY, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) - Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company…
Read attachment ↗